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A B S T R A C T
Vitamin D3 regulates genes critical for human health and its deﬁciency is associated with an increased
risk for osteoporosis, cancer, diabetes, multiple sclerosis, hypertension, inﬂammatory and immunological
diseases. To study the impact of vitamin D3 on genes relevant for the transport and metabolism of
nutrients and drugs, we employed next-generation sequencing (NGS) and analyzed global gene
expression of the human-derived Caco-2 cell line treated with 500 nM vitamin D3. Genes involved in
neuropeptide signaling, inﬂammation, cell adhesion and morphogenesis were differentially expressed.
Notably, genes implicated in zinc, manganese and iron homeostasis were largely increased by vitamin D3
treatment. An 10-fold increase in ceruloplasmin and 4-fold increase in haptoglobin gene expression
suggested a possible association between vitamin D and iron homeostasis. SLC30A10, the gene encoding
the zinc and manganese transporter ZnT10, was the chieﬂy affected transporter, with 15-fold increase in
expression. SLC30A10 is critical for zinc and manganese homeostasis and mutations in this gene,
resulting in impaired ZnT10 function or expression, cause manganese intoxication, with Parkinson-like
symptoms. Our NGS results were validated by real-time PCR in Caco-2 cells, as well as in duodenal
biopsies taken from healthy human subjects treated with 0.5 mg vitamin D3 daily for 10 days. In addition
to increasing gene expression of SLC30A10 and the positive control TRPV6, vitamin D3 also increased
ZnT10 protein expression, as indicated by Western blot and cytoﬂuorescence. In silico identiﬁcation of
potential vitamin D responsive elements (VDREs) in the 50-ﬂanking region of the SLC30A10 promoter and
dual-luciferase reporter assay showed enhanced promoter activity in the presence of vitamin D receptor
(VDR) and retinoid X receptor (RXR) constructs, as well as vitamin D3, but not when one of these factors
was absent. Electrophoretic mobility shift assay (EMSA) and competition EMSA revealed binding of select
sequences, namely, nt 1623/-1588 and nt 1758/-1723 relative to the transcription start site, to VDR-
containing nuclear extracts. In conclusion, we have shown that vitamin D3 transactivates the
SLC30A10 gene in a VDR-dependent manner, resulting in increased ZnT10 protein expression. Because
SLC30A10 is highly expressed in the small intestine, it is possible that the control of zinc and manganese
systemic levels is regulated by vitamin D3 in the intestine. Zinc, manganese and vitamin D are important
for bone metabolism and brain health. Future examination of a possible role for supplementation or
chelation of zinc and manganese, alongside vitamin D3 administration, will further our understanding of
its potential beneﬁt in the treatment of speciﬁc illnesses, such as osteoporosis and Parkinson’s disease.
ã 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Vitamin D is involved in several physiological processes,
ranging from inﬂammation to glucose homeostasis and blood
pressure, to name a few [1]. Deﬁciency in vitamin D is pandemic [2]* Corresponding author at: Department of Clinical Pharmacology and Toxicology,
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atric disorders [3]. While vitamin D can be obtained from fatty ﬁsh
and fortiﬁed foods, its main natural source is the provitamin D, 7-
dehydrocholesterol, found in the skin. Photochemical conversion
of 7-dehydrocholesterol, initiated by skin exposure to UV light, is
the ﬁrst step in the production of the biologically active vitamin D
hormone. The product of this conversion is carried to the liver,
where it is transformed into 25-hydroxyvitamin D (25OHD), which
is then oxidized, predominantly in the kidney, to form the active
hormone 1,25-dihydroxyvitamin D (1,25D), or vitamin D3. To exert
its gene regulatory effect, vitamin D3 binds to the vitamin Dunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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receptor (RXR) and binds vitamin D response elements (VDREs) in
the promoter region of target genes, culminating in transcriptional
activation or repression. Genes thus regulated include the calcium
channel transient receptor potential vanilloid 6 (TRPV6) [4], the
vitamin D3 24-hydroxylase CYP24A1 [5] and the organic anion
transporting polypeptide 1A2 (SLCO1A2; OATP1A2) [6]. Our
present data shows that treatment of human derived Caco-2 cells
with vitamin D3 altered gene expression of these and other genes
relevant for a variety of physiological processes, including drug
metabolism and transport. Iron homeostasis was among the most
affected processes and may suggest that a correlation between
vitamin D3 levels and iron regulation exists at the molecular level.
Our results also indicate that expression of the SLC30A10 gene, as
well as its encoded protein, the zinc (Zn) and manganese (Mn)
transporter ZnT10, are augmented by vitamin D3 treatment in
Caco-2 cells. SLC30A10 mRNA is predominantly expressed in
human liver, brain, testis and small intestine [7,8]. Missense and
nonsense mutations in this gene, impairing ZnT10 expression or
cell surface trafﬁcking, cause manganism – a Parkinson-like
autosomal recessive disease characterized by dystonia, hyper-
manganesemia, steatosis, cirrhosis and polycythemia [9]. By
means of its Mn efﬂux action, ZnT10 protects the CNS from
manganese toxicity and ZnT10 dysfunction leads to accumulation
of Mn in the liver and nervous system [10], even in patients
without prior history of environmental exposure to high Mn levels
[8]. Zn and Mn are classiﬁed as trace elements or micronutrients
because they are essential for human health albeit needed in small
quantities, whereas at high concentrations, they exhibit toxic
effects [11]. It is interesting to note that, in addition to the
renowned vitamin D and calcium contributions, Zn and Mn are
crucial for bone metabolism [12]. They are absorbed from the
intestine [10], where the gene encoding ZnT10, SLC30A10, is highly
expressed at the mRNA level [7] and where the VDR is also
abundant [13]. Because our results indicate that vitamin D3
induces SLC30A10 gene and protein expression, it is likely that the
control of Zn and Mn systemic levels begins in the intestine and is
dependent on the vitamin D nutritional status.
2. Material and methods
2.1. Cell culture
The human-derived Caco-2 cell line (LGC Promochem, Molsheim,
Switzerland) was cultured in Dulbecco’s modiﬁed Eagle’s medium
(ThermoFisher) containing 10% fetal bovine serum (Chemie
Brunschwig) and 1000 U/mL and 1000 g/mL penicillin and strepto-
mycin, respectively (Invitrogen, Carlsbad,CA). Cells were maintained
at 37 C, in a humidiﬁed atmosphere containing 5% CO2.
2.2. Next generation sequencing (NGS)
Caco-2 cells were treated with 500 nM 1,25 dihydroxyvitamin
D3 (vitamin D3) or vehicle (ethanol; EtOH) for 8 h, 24 h, 48 h and
72 h. Cells were harvested in TRIzol1 and total RNA was isolated
using the guanidinium thiocyanate-phenol-chloroform extraction
method. At the Functional Genomics Center Zurich, the isolated
RNA was reverse-transcribed and ampliﬁed by PCR, then
next-generation sequencing on the Illumina HiSeq 2000 (TruSeq
SBS Kit v3-HS (Illumina)) was performed. Changes were consid-
ered signiﬁcant when p value 0.05 and the increase or decrease in
expression was at least 40% (log2 ratio 0.5 or   0.75) compared
to the vehicle control (EtOH). MetaCore online service (Thomson
Reuters) was employed for gene ontology and network analysis.
Select genes altered by vitamin D3 in the NGS data were chosen for
further investigation.2.3. Vitamin D3 administration in healthy human volunteers
In a prospective single-center study performed at the Universi-
ty of Zurich, six female and four male healthy volunteers (aged
24–29 years, mean 26 years, median 26 years) self-administered
1,25 dihydroxyvitamin D3 (Rocaltrol1) 0.5 mg per day for 10 days.
Duodenal biopsies were collected by gastroscopy before (“FIRST”
gastroscopy) and after (“SECOND” gastroscopy) the onset of
Rocaltrol1 administration and were immediately frozen in liquid
nitrogen. Subsequently, biopsies were analyzed by real-time PCR
(RT-PCR) as described in the next Section (2.4), to conﬁrm gene
changes observed in the NGS data. This study was performed in
conformity with the Good Clinical Practice guideline ICH E6 after
having been approved by the ethical committee of the Canton of
Zurich (license number 2012-0051) and registered at clinicaltrials.
gov (NCT01856348). All volunteers signed the informed consent.
2.4. Analysis of duodenal biopsies and Caco-2 cells by real-time PCR
Extraction of RNA from duodenal biopsies and Caco-2 cells was
performed using the Nucleospin miRNA kit (Macherey-Nagel, Inc.).
Prior to processing, duodenal biopsies were homogenized with a
1.5 mL pestle (VWR cat. # 47747-358, European Article #
431-0094) following recommendations from the Nucleospin
miRNA kit’s manufacturer. After tissue homogenization, biopsies
and Caco-2 cells were processed similarly. Extracted RNA was
subsequently evaluated by RT-PCR for selected drug and nutrient
transporters, using TaqMan probes (ThermoFisher). Data obtained
was normalized to the housekeeping genes villin (biopsies) or
beta-actin (Caco-2 cells).
2.5. Isolation of a total membrane fraction from cultured Caco-2 cells
Caco-2 cells grown in 10 mm petri dishes were treated with
500 nM 1,25 dihydroxyvitamin D3 (vitamin D3) or vehicle (ethanol;
EtOH) for 72 h with refreshment of vitamin D3 or EtOH every 24 h.
The following procedure was performed on ice. Brieﬂy, cells were
washed 3x in 10 mL of 0.9% (w/v) NaCl solution, followed by
1 addition of 10 mL 250 mM sucrose solution. Subsequently, 3 mL
ice-cold 5 mM sucrose solution, containing 5 mM phenylmetha-
nesulfonyl ﬂuoride (PMSF; freshly added from a 200 mM stock in
EtOH) and 1 mg/ml antipain/leupeptin (freshly added from
1 mg/ml stock each) was added and cells were scraped with a
rubber policeman, then transferred to a tight ﬁtting glass-teﬂon
potter on ice and homogenized with 20 strokes at full speed.
Homogenate was then centrifuged at 4 C for 10 min at 2950 rpm
(900gav) in a Sorvall SS34 rotor and the supernatant was carefully
removed and centrifuged at 4 C for 20 min at 9600 rpm (8500 gav)
in a Sorvall SS34 rotor. Next, the resulting supernatant was
carefully removed and centrifuged at 4 C for 1 h, at 38,200 rpm
(100,000gav) in a TFT 65.13 rotor or at 360400 rpm (100,000gav) in a
TFT 70.38 rotor. After complete removal of the supernatant,
500 mL of a 250 mM sucrose solution containing protease
inhibitors was added to the precipitate and this suspension was
homogenized with a 1 mL syringe and a thin needle. Approxi-
mately 10–20 mL of the resulting solution was separated for
protein determination and the remaining membrane fraction was
stored in liquid nitrogen until use.
2.6. Western blotting
Lysates containing 20 mg of protein from the isolated
Caco-2 membrane fraction described above were separated by
SDS-PAGE and blotted on polyvinylidene diﬂuoride membranes
(Millipore). Membranes were blocked with TBS containing 0.1%
Tween 20 (TBST) and 3% BSA, for 1 h, at room temperature. The
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HPA017989) and the plasma membrane control goat anti-Na + K +
ATPase (Santa Cruz, sc-16041) were then incubated overnight at
4 C. After washing the membranes with TBST, blots were treated
with horseradish peroxidase conjugated secondary antibodies at
room temperature for 1 h, washed again with TBST and developed
using the ECL Plus detection system (Amersham Biosciences, Little
Chalfont, UK).
2.7. Cytoﬂuorescence
Caco-2 cells grown on3 mm slides were treated with 500 nM
1,25 dihydroxyvitamin D3 (vitamin D3) or vehicle (ethanol; EtOH)
for 72 h with refreshment of vitamin D3 or EtOH every 24 h. After
treatment, cells were washed with cold PBS, ﬁxed in 4%
paraformaldehyde, and treated with 0.1% Triton X in PBS for
15 min and with 0.1% Tween-20 in 1% BSA/PBS for 30 min. Then,
cells were incubated with rabbit anti-SLC30A10 (Sigma-Aldrich,
HPA017989) antibody at 4 C overnight. Cells were then washed
and incubated with secondary antibody for 1 h at room tempera-
ture, in the dark. After being washed, cells were counterstained
with 40-6-diamidino-2-phenylindole (DAPI; Vector Laboratories)
and slides were mounted and visualized under a ﬂuorescent
microscope (Leica DMI6000B).
2.8. Identiﬁcation of VDREs in silico and DNA constructs
In silico analysis of the 50-ﬂanking region enclosing 3.6 kb
upstream the transcription start site (TSS) and 211 bp down-
stream the ATG start codon, i.e., 3622/ + 211, of theFig. 1. Effect of vitamin D treatment on gene expression patterns in Caco-2 cells. (A) Sum
control (EtOH). Genes that are differentially increased or decreased after Vit D treatment
560 genes with signiﬁcantly changed expression after Vit. D treatment for 24 h, 208 gene
with a 1.4 fold increased expression (orange bars). (C) GO analysis of genes with a 1.4 fo
expression of 1.4 fold across treatment groups. The top 5 results are listed. All analy
interpretation of the references to colour in this ﬁgure legend, the reader is referred toSLC30A10 promoter, revealed several conjectural vitamin D
response elements (VDREs). This analysis was performed with
the online transcription factor binding site prediction tools PROMO
[14,15] and MatInspector [16,17], as well as by visual inspection of
canonical sites, based on sequences described in Toell et al. [18].
This 3.8 kb region was then synthesized, cloned and subcloned
into the pGL3 basic luciferase reporter vector (Promega) using
GeneArt services, for subsequent dual-luciferase reporter assay.
Brieﬂy, the synthesized fragment was cloned into the pMK vector,
carrying a kanamycin resistance gene, and was then subcloned into
the Nhe/XhoI-digested pGL3 basic vector. Dual-luciferase reporter
assay was carried out as described below (Section 2.9). In silico
predicted VDREs were also incorporated in the design of
oligonucleotides used in electrophoretic mobility shift assay
(EMSA), as described in Section 2.10.
2.9. Dual-Luciferase reporter assay
Caco-2 cells were seeded in 48-well plates and transiently
transfected at a conﬂuence of approximately 80%, on the next day.
The transfection agent Fugene HD (Promega) was used to deliver
DNA to the cells, in a transfection mixture containing 400 ng of the
pGL3 basic constructs (Section 2.8) and 200 ng of VDR and/or RXR
expression plasmid in pCMX. The pCMX-VDR and pCMX-RXR
plasmids were kindly donated by Dr. David Mangelsdorf (Univer-
sity of Texas Southwestern Medical Center, Dallas, TX). In each
well, 100 ng of phRG-TK Renilla reniformis luciferase reporter
plasmid (Promega) was co-transfected to account for variations in
transfection efﬁciency. An appropriate volume of 1a,25-dihydrox-
yvitamin D3 (Sigma-Aldrich) or its vehicle EtOH, was added to eachmary of differentially expressed genes between Vit. D treatment for 24 h and vehicle
 are indicated by orange and green bars, respectively. Cut off 1.4-fold, p < 0.05. Of all
s are increased and 352 genes are reduced. (B) Gene ontology (GO) analysis of genes
ld decreased expression (green bars). (D) Network analysis of genes with a change of
ses were performed with the MetaCore online software (Thomson Reuters). (For
 the web version of this article.)
Table 1
Gene expression of metabolizing enzymes signiﬁcantly affected by Vit. D treatment
in Caco-2 cells for 24 h. Gene expression levels are quantiﬁed as log2 ratio of
treatment (vitamin D3) vs. control (EtOH) and converted with 2^(log2ratio) to denote
fold change: 0.5 corresponds to 1.41 fold change, i.e., 41% increase in gene
expression.
Increased Metabolizing Enzymes
Gene Fold change log2 Ratio p Value
CYP24A1 1184.45 10.21 0
UGT1A1 5.34 2.418 1.22E-10
SULT1C2 5.34 2.417 2.11E-35
CYP3A4 3.64 1.863 0.0008559
CYP26A1 2.75 1.462 0.01259
CYP2S1 2.25 1.168 3.47E-81
NAT8B 1.69 0.7585 0.02615
NAT8 1.65 0.722 0.02123
CYP3A5 1.64 0.7173 5.54E-33
CYP1A1 1.58 0.656 3.79E-15
CYP2C19 1.53 0.6158 0.04933
Decreased Metabolizing Enzymes
Gene Fold change log2 Ratio p Value
CYP4B1 0.46 1.124 0.04988
SULT1B1 0.51 0.9653 0.01921
NAT2 0.56 0.8267 0.01868
CYP4X1 0.58 0.7797 0.002375
Table 2
Gene expression of nutrient and drug transporters signiﬁcantly affected by Vit. D
treatment in Caco-2 cells for 24 h. Gene expression levels are quantiﬁed as log2 ratio
of treatment (vitamin D3) vs. control (EtOH) and converted with 2^(log2ratio) to
denote fold change: 0.5 corresponds to 1.41 fold change, i.e., 41% increase in gene
expression.
Increased Transporters
Gene Fold change log2 Ratio pValue Protein
SLC30A10 15.13 3.919 5.65E-23 ZnT10
SLCO1A2 2.30 1.201 0.0001578 OATP1A2
SLC27A2 2.17 1.121 2.55E-82 FATP2
SLC46A1 2.06 1.042 5.47E-132 PCFT
SLC46A2 2.01 1.007 0.04443 TSCOT
SLC2A9 1.76 0.819 0.00931 GLUT9
ABCC2 1.64 0.714 3.31E-40 MRP2
ABCB1 1.63 0.705 1.02E-27 MDR1/Pgp
SLC1A3 1.51 0.594 1.02E-31 EAAT1
SLC25A20 1.43 0.518 9.84E-17 CAC
Decreased Transporters
Gene Fold change log2 Ratio pValue Protein
SLC22A11 0.38 1.403 3.62E-05 OAT4
SLC2A2 0.54 0.8975 0.005613 GLUT2
SLC39A2 0.56 0.8417 0.004084 ZIP-2
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tion of 500 nM. Twenty four hours post-treatment, cells were lysed
with 50 mL of the passive lysis buffer provided in the Dual-
Luciferase1 Reporter (DLRTM) Assay System kit (Promega) and
10 mL of lysate were transferred to a 96-well plate. Luciferase
activity was measured with the substrates LAR II and Stop & Glo1,
also included in the kit, using a GloMax-Multi detection system
(Promega). Values obtained for ﬁreﬂy luciferase activity were
normalized to renilla’s activity, as well as empty vectors such as
pGL3-basic or pcDNA3.1. In each experiment, tested conditions
were performed in triplicate.
2.10. Electrophoretic mobility shift assay
Electrophoretic Mobility Shift Assay (EMSA) oligos were
designed based on in silico predicted VDREs, with added 50-AGCT
(fwd) or 50-GATC (rev) overhangs to allow for their radioactive
ﬁlling-in reactions, as described previously [19] and indicated in
Table 2. They were annealed and subsequently labeled with [32P]-
dATP, using Multiscribe reverse transcriptase (Life Technologies).
Nuclear extracts from Caco-2 cells at 70–80% conﬂuence were
quantiﬁed with the PierceTM BCA Protein Assay Kit (Thermo
Scientiﬁc). Appropriate binding reactions were performed using
NE-PER kit (ThermoScientiﬁc) and carried out as described [19].
The oligonucleotide named VDREcon, carrying the VDRE consen-
sus sequence AGGTCA in a DR3 repeat, was used as positive control
in EMSA. In competition EMSA, unlabeled VDREcon was employed
at 100 ng (Cold VDREcon_1) and 200 ng (Cold VDREcon_2), to
compete with 150 ng of the labeled oligos for the VDR.
2.11. Statistical analysis
Gene ontology (GO) and Network analysis of the
next-generation sequencing data were performed with the
MetaCore online software (Thomson Reuters). Dual-luciferase
assay data were analyzed with One-way analysis of variance
followed by Dunnett’s post-hoc test, using GraphPad 5.0. Error bars
represent the standard error of the mean values from at least
3 experiments. Differences between treatment and controls (*)
were considered signiﬁcant when p  0.05.
3. Results
3.1. Global effects of Vitamin D3 in Caco-2 cells: next generation
sequencing (NGS)
Vitamin D3 plays an important role in the regulation of several
SLC transporters and metabolizing enzymes. Caco-2 cells were
treated with vitamin D3 for 24 h and total RNA was extracted and
analyzed by NGS. Changes in gene expression were considered
signiﬁcant when p value 0.05 and expression was at least 41%
increased (log2 ratio 0.5) or decreased (log2 ratio   0.75),
compared to the vehicle control (EtOH). Consistent with previous
reports, vitamin D3 increased expression of genes implicated in its
own catabolism, namely, CYP24A1 and CYP3A4, as well as genes
involved in calcium homeostasis, such as the calcium channel
TRPV6, implicated in intestinal calcium absorption. The acknowl-
edged mechanism by which these inductions occur is by VDR
binding to VDREs in the promoter regions of these genes [4,20–22].
Of all 208 upregulated and 352 downregulated genes signiﬁcantly
affected (Fig. 1), vitamin D3 24-hydroxylase CYP24A1 showed the
strongest change in expression, with an increase of above 1000-
fold and was followed by the calcium channel TRPV6, with over
100-fold increase (log2 ratio(24h) = 6.989; p-value = 5.37e56). Also
consistent with previous reports [23], vitamin D3 increased
expression of the cytosolic sulfotransferase SULT1C2. The UDPglycosyltransferase UGT1A1 and the retinoic acid hydroxylase and
CYP26A1 were among the relevant metabolizing enzymes whose
expression was augmented by vitamin D3 (Table 1).
NGS data endorsed our previous observations that vitamin D3
transactivates the organic anion transporting polypeptide 1A2
(OATP1A2; SLCO1A2 gene) and the proton-coupled folate trans-
porter (PCFT; SLC46A1 gene) [6,24]. Here, their expression levels
increased by approximately 2-fold each (Table 2). Vitamin D3 also
enhanced expression of nutrient transporters such as the fatty acid
transport protein (FATP2; SLC27A2) and the carnitine/acylcarnitine
carrier (CAC; SLC25A20). In contrast, expression of genes encoding
the organic anion transporter 4 (OAT4; SLC22A11) and the glucose
transporter 2 (GLUT2; SLC2A2) was considerably reduced. In
addition to the OATP1A2, PCFT and OAT4, which transport
Table 3
Degree of change in gene expression for selected pathways affected by Vit. D treatment of Caco-2 cells for 24 h.
Vit D 24-hydroxylase activity
CYP24A1 (10.21), CYP3A4 (1.86)
Iron homeostasis
CP (3.30), HP (1.99), SLC46A1 (1.04), FTH1 (0.25), SLC25A37 (0.18), CYBRD1 (0.24), HFE (0.26), SLC40A1 (0.34), EPOR (0.32), SLC39A2 (0.84), TTYH1 (2.14)
CP = ceruloplasmin, HP = haptoglobin, SLC46A1 = PCFT/HCP1, FTH1 = ferritin, HFE = hemochromatosis, SLC40A1 = ferroportin, EPOR = erythropoietin, TTYH1 = tweety family
member 1. Numbers in parentheses indicate gene expression levels quantiﬁed as Log2 ratios. When converted with 2^(log2ratio), they indicate fold changes: (0.5) corresponds to
a 1.41 fold, or 41%, change in gene expression.
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fexofenadine (OATP1A2), methotrexate (PCFT) and torasemide
(OAT4), the efﬂux transporters multidrug resistance-associated
protein 2 (MRP2) and the P-glycoprotein-1 (P-gp) also responded
to vitamin D3 treatment in Caco-2 cells (Table 2).
Network analysis shows iron homeostasis among the top
differentially expressed pathways due to vitamin D3 treatment,
alongside with neuropeptide signalling, inﬂammation, cell adhe-
sion and morphogenesis (Fig. 1D). These results agree with several
reports on the putative or conﬁrmed modulatory effects of vitamin
D in innate and adaptive immunity, cell growth and differentiation
[10,25–27]. Among the genes involved in iron homeostasis, the
iron oxidase ceruloplasmin (10-fold increase), the hemoglobin
binding protein haptoglobin (4-fold increase), and SLC46A1, also
known as the heme-iron carrier 1 (HCP1) [28], had the most
remarkable increase in gene expression. In contrast, expression of
SLC39A2 and the tweety family member 1 (TTYH1) were
signiﬁcantly reduced (Table 3). While TTYH1 is possibly an iron
transporter [29], SLC39A2 was shown to play an important role in
iron homeostasis in zinc deﬁcient mice [30]. SLC39A2 is part of the
ZIP (SLC39) family, implicated in zinc, iron and/or manganese
transport [31].
Vitamin D has been shown to have beneﬁcial effects in
neurological diseases where neuropeptide, especially glutamate,
signaling is dysregulated, such as schizophrenia [32] and
Parkinson’s disease [33–35]. Our NGS data shows an 50%
increase in the glutamate transporter gene SLC1A3 (Table 2).
While genes involved in peptide, amide and sulfur compound
binding, glutathione transferase and the majorFig. 2. Vitamin D3 increases SLC30A10 gene expression time-dependently. Gene express
actin, from Caco-2 cells treated with 500 nM vitamin D3 or EtOH, at different time-poihistocompatibility complex (MHC) class II are downregulated
by vitamin D3 in Caco-2 cells (Fig. 1C), genes involved in
enzymatic catalysis, heme and oxygen binding and serine-type
endopeptidase activity are upregulated, as revealed by GO
analysis (Fig. 1B).
Of all genes that showed increased expression with vitamin D3
treatment, SLC30A10 was the fourth most strongly affected. It was
also the chief affected transporter gene, with 15-fold increase in
expression (Table 2). A concomitant 45% decrease in expression
of the other zinc transporter, SLC39A2, is noteworthy. These zinc
transporters work in opposite directions to maintain zinc
homeostasis. While members of the ZnT (SLC30) family reduce
Zn2+ cytoplasmic concentrations via efﬂux through the plasma
membrane or uptake into cytoplasmic organelles, ZIP (SLC39)
transporters increase cytoplasmic zinc concentrations by zinc
uptake from the extracellular space or efﬂux from intracellular
storage organelles [36]. SLC30A10 is mostly located in the brain,
retina, liver and small intestine [7,37], while SLC39A2 has a
widespread tissue distribution [38].
3.2. Vitamin D3 increases SLC30A10 expression in duodenal biopsies
and Caco-2 cells: real-time PCR
Real-time PCR validated the NGS observations of strong
induction of SLC30A10 by vitamin D3. Caco-2 cells were treated
with 500 nM 1,25 dihydroxyvitamin D3 (vitamin D3) or vehicle
(EtOH) for 8 h, 24 h, 48 h and 72 h and the effect of vitamin D3 on
SLC30A10 was already observed after 8 h of treatment, while it
peaked at 48 h (Fig. 2). This rapid onset, but slow reaching ofion measured with RT-PCR for SLC30A10 (A) and TRPV6 (B) and normalized to beta
nts.
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SLC30A10 induction by vitamin D3, possibly with genomic
(VDR-mediated regulation of transcription) and non-genomic
(activation of signal transduction pathways upon binding to a cell
surface receptor) vitamin D3 modes of action [1]. A strong vitamin
D3 effect was also observed for TRPV6 at all time points. Because
TRPV6 is known to have a functional VDRE [4,22] and is highly
expressed in the duodenum [39], it was considered a suitable
positive control in the RT-PCR measurements in Caco-2 cells, as
well as in human duodenal biopsies. Biopsies were collected from
healthy human volunteers, before and after oral administration of
0.5 mg 1,25-dihydroxyvitamin D3 for 10 days. All biopsy-derived
mRNA measurements were normalized to villin. TRPV6 induction
was noticeable in 70% of the duodenal biopsies, whileFig. 3. Vitamin D3 oral administration increases SLC30A10 and TRPV6 gene expression i
(SECOND) Rocaltrol1 10 days-treatment, in human healthy volunteers. Biopsies were pSLC30A10 expression was augmented in 60% of the biopsies
(Fig. 3).
3.3. Vitamin D3 increases ZnT10 protein expression in Caco-2 cells:
Western blotting and cytoﬂuorescence
Protein expression at the cell surface is critical for the
ZnT10 efﬂux activity and its protective role against Mn toxic
accumulation. Mutations in SLC30A10 that result in
ZnT10 retention in the endoplasmic reticulum are linked to
cases of familial parkinsonism, presenting with Mn accumula-
tion in the liver and the CNS [8,40]. To determine if the vitamin
D3-induced augmentation of SLC30A10 gene expression leads to
an increase in ZnT10 protein at the cell surface, we ﬁrst seededn duodenal biopsies. RT-PCR of duodenal biopsies collected before (FIRST) and after
rocessed as described in methods, Sections 2.3 and 2.4.
Fig. 4. ZnT10 expression is induced by Vitamin D3 treatment. A, representative western blot of ZnT10 and the cell surface control Na+-K+ ATPase, from isolated membrane
fractions of Caco-2 cells treated with vehicle (Cont) or Vitamin D3 (VitD). B, representative staining of Caco-2 cells from vehicle (Cont) or vitamin D3 (VitD) treatment groups
for ZnT10 protein (red). Cells were counterstained with DAPI (blue). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
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then treated the cells with vitamin D3 or control (EtOH). We
subsequently prepared slides for immunoﬂuorescence detection
(Section 2.7) and isolated the membrane fraction of cells grown
in the petri dishes (Section 2.5) for Western blotting (Sec-
tion 2.6), using an anti-SLC30A10 antibody. Vitamin D3
treatment clearly increased ZnT10 protein levels at the cell
surface, as shown by enhanced immunoﬂuorescence along the
cell borders in treated cells, compared to control (Fig. 4B). A
notable increase in immunoblotting signal for ZnT10, but not
the negative control Na+/K+-ATPase, is also observed in vitamin
D3-treated, but not untreated cells (Fig. 4A). These observations
support the hypothesis that vitamin D3 is important for
SLC30A10-mediated Zn and Mn homeostasis.
3.3. Vitamin D3 activates the SLC30A10 promoter: reporter gene assay
VDR-responsive elements (VDREs) have been found in numer-
ous genes important for calcium homeostasis and vitamin D
metabolism, such as TRPV6 and CYP24A1, as well as genes that do
not appear to have direct implications in calcium homeostasis,
such as SLCO1A2 and SLC46A1 [6,24]. These genes respond to
vitamin D3 with an increase in gene expression. Our results show
that vitamin D3 increases SLC30A10 expression at the mRNA and
protein levels, prompting us to study whether this is a VDR-
mediated effect. We employed the in silico prediction tools PROMO
[14,15] and MatInspector [16,17], as well as visual inspection [18]
and examined the region in the SLC30A10 promoter encompassing3622 nucleotides in the 50-ﬂanking region of the gene, relative to
the TSS (position +1), and 211 nucleotides upstream the ATG start
codon, i.e., 3622/ + 211 or 3.8 kb, using RefSeq
NG_032153.1 from the National Center for Biotechnology Informa-
tion database (Fig. 5A). Because 13 conjectural VDREs were
predicted, the DNA sequence corresponding to 3.8 kb upstream
the ATG was used to construct a reporter plasmid in pGL3 basic, as
described in Section 2.8 and indicated in the cartoon in Fig. 5B. The
resulting construct was tested for promoter activity in a
dual-luciferase assay. Classically, heterodimerization of the nucle-
ar VDR with RXR is necessary for VDR-dependent induction to
occur. After cotransfecting Caco-2 cells with VDR-pCMX and RXR-
pCMX, or with the negative control vector pcDNA3.1, the
SLC30A10 promoter construct was incubated with vitamin D3 or
vehicle (EtOH). As shown in Fig. 5B, luciferase activity increased
signiﬁcantly in the presence of VDR, RXR and vitamin D3, but not
with either transcription factor alone or when vitamin D3 was
replaced with EtOH. This observation indicates that the
SLC30A10 promoter is transcriptionally activated by vitamin D3
and that VDR and RXR are required to confer this induction.
3.4. VDR binds to the SLC30A10 promoter region: electrophoretic
mobility shift assay
After showing that the 50-ﬂanking region of the SLC30A10 gene
is activated by vitamin D3 in reporter gene assays and may contain
a functional VDRE, we aimed to identify the VDRE or VDREs
responsible for this effect. Based on the in silico predicted VDRE
Fig. 5. SLC30A10 promoter sequence and reporter gene activity. (A) 50-ﬂanking region 3.8 Kb upstream the SLC30A10 gene start codon (ATG). Putative VDREs and the ATG
start codon are highlighted in blue and red, respectively, and EMSA oligos are enclosed in boxes. NCBI RefSeq NG_032153.1. (B) SLC30A10 promoter activity measured by dual-
luciferase reporter assay. Caco-2 cells were transiently transfected with the SLC30A10 promoter region 3622/ + 211 (relative to the TSS) in the luciferase reporter vector
pGL3 basic. Expression plasmids of the human VDR (pCMX) and/or RXR (pCMX) or empty vector (pCDNA3.1), as well as the transfection efﬁciency control phRG-TK Renilla
reniformis luciferase reporter plasmid, were co-transfected. Vitamin D3 or EtOH was added 2 h post-transfection, in a ﬁnal concentration of 500 nM and incubated for 24 h,
after which cells were harvested and luciferase and renilla activities measured. Fireﬂy luciferase values were normalized to renilla’s values in each well, and data was
normalized to the appropriate empty vectors. Bars represent the standard error of the mean for three independent experiments, each performed in triplicate. Results were
analyzed with One-way analysis with Dunnett’s post-hoc test in GraphPad 5.0b, with differences being considered signiﬁcant (*) when p  0.05.
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overhangs, to allow for their radioactive ﬁlling-in reactions
(Table 4), and tested them in EMSA. As evidenced from the
resulting DNA-protein shift (Fig. 6A), nuclear extracts from human-
derived Caco-2 cells showed protein binding activity to DNA
sequences located at 1623/-1588 (oligo #1), and 1758/-1723
(oligo#2), but not 3367/-3332 (oligo#3), from the transcription
start site. As a positive control we used the EMSA probe that we
showed previously to correspond to the SLCO1A2 VDRE at +202/
+216 [6]. We then used a molar excess of cold probe containing a
canonical VDRE sequence, namely VDREcon, to compete with
radioactively labeled (hot) oligo#1 and oligo#2 for VDR binding
(Fig. 6B). Disappearance of the DNA-protein shift band in the
presence of competitor conﬁrms that the VDR binds to the
SLC30A10 promoter region, at nt 1623/-1588 (oligo #1), and nt
1758/-1723 (oligo#2) relative to the TSS.
4. Discussion
Vitamin D is essential for human health. Its active form, the
hormone 1,25-dihydroxyvitamin D (1,25D), or vitamin D3, has
pleiotropic effects beyond calcium homeostasis and bone
metabolism. Vitamin D deﬁciency is associated with increased
risk for osteoporosis, cancer, diabetes, multiple sclerosis, hyper-
tension, inﬂammatory and immunological diseases, among other
illnesses [41]. Classically, the vitamin D3 effects are mediated by
the VDR, which in turn is estimated to regulate the expression ofTable 4
Top strands of oligonucleotides used as EMSA probes, numbered relative to t
NG_032153.1).
Oligonucleotide ID 
SLC30A10(-1623/-1588)fwd oligo #1 
SLC30A10(-1758/-1723)fwd oligo #2 
SLC30A10(-3367/-3332)fwd oligo #3 
VDRE consensus probe_fwd VDREcon 
SLCO1A2(+202/ + 216)fwd OATP1A2 about 500 human genes [1]. Our current NGS results from vitamin
D3-treated Caco-2 cells corroborated previous observations that
vitamin D3 increases expression of the vitamin D hydroxylase
CYP24A1, SULT1C2 and SLCO1A2 [4,6,20–24] (Table 2), as well as
of genes involved in neuropeptide signalling, inﬂammation, cell
adhesion and morphogenesis [10,25–27] (Fig. 1D). In line with the
pleiotropic nature of vitamin D3 effects, we observed alterations
in genes with distinct functions, many of which are important for
nutrient and drug transport, as well as phase I and phase II
metabolism (Tables 1 and 2). Iron and heme metabolism were
revealed by network analysis as greatly affected by vitamin D3
treatment in Caco-2 cells. These observations were further
corroborated by GO analysis, where genes involved in oxygen
and heme binding were among those affected most by vitamin D3
treatment (Fig. 1B). While additional experiments would be
useful to verify these outcomes in vivo, for example, the effect of
VDR knockout on iron homeostasis, our current results may
provide a preliminary molecular basis for a conceivable link
between vitamin D status and iron homeostasis. This link can be
inferred from in vivo animal studies and clinical human data. For
instance, four weeks’ administration of high doses of dietary
vitamin D3 to Wistar rats enhanced iron intestinal absorption and
hepatic iron stores [42], while, conversely, rats fed an iron
deﬁcient diet exhibited decreased serum vitamin D and bone
mineral density (BMD) [43]. In a randomized controlled double-
blind trial with iron-deﬁcient menstruating women, enhancement
of erythropoiesis and iron status was only achieved when
skimmed milk was fortiﬁed with vitamin D and iron, but not
iron alone [44]. Although a direct vitamin D involvement pends
conﬁrmation, vitamin D deﬁciency appears to increase the risk of
anemia in healthy female children and adolescents [45]. Iron
deﬁciency has been hypothesized as a risk factor for osteoporosis
[46]. Overall, our data support an association between the effects
of vitamin D and iron at the molecular level that would warrant
further investigation.
Expression of various transporter genes was signiﬁcantly
altered by vitamin D3 in Caco-2 cells. SLC30A10, encoding the
zinc and manganese transporter ZnT10, was the transporter with
the highest increase in gene expression, with remarkable increase
in protein expression as well, and we hereby show that trans-
activation by the VDR is responsible, at least partly, for this
response. Zinc and manganese are trace elements whose concen-
trations need to be tightly regulated to prevent the toxic effects of
their accumulation in the body. Zinc is required for the activity of
several enzymes, including DNA and RNA polymerases, for the
immune system and as a structural component of transcription
proteins. Among the many pathological consequences of Zn
deﬁciency are growth impairment, dermatitis, diarrhea and
neuropsychological diseases [47], whereas surges in its systemic
levels correlate with anemia, leukopenia, neutropenia, copper and
iron deﬁciency [48]. Manganese is important for bone develop-
ment, lipid, carbohydrate and amino acid metabolism [11], but in
high concentrations, causes parkinsonism, dystonia, hypermanga-
nesemia, steatosis, cirrhosis and polycythemia [9]. The need to
keep these micronutrients at a narrow concentration range ishe transcriptional start site of the human SLC30A10 gene (NCBI RefSeq
Sequence (50–30)
AGCTATCTTGAACTCCTGGGTTCAAGTGATCCTCCCACCT
AGCTTCTCGACTTCTTGGGTTCAAGCCTTCCTCCCACTTT
AGCTGAGTTTGATGCCTAGTTCAGAGCTCAAATCTATCAA
AGCTGCAGGGGGAGGTCAAAGAGGTCACACTAGTA
AGCTTCAGAAAGGGAACTCCCTGACCCCTTGAGCT
Fig. 6. EMSA showing the VDRE motifs in the SLC30A10 promoter. Double-stranded, radiolabeled oligos at 3367/-3332 (oligo#3), 1623/-1588 (oligo#1) and 1758/-1723
(oligo#2) were co-incubated with binding reaction containing Caco-2 nuclear extract. (A) Only oligos #1 and #2 showed DNA-protein shift bands similar to the positive
control OATP1A2 DR3 motif +202/ + 216. (B) Competition EMSA whereby 200 ng of either radiolabeled oligo#1 or oligo#2 were competed off with cold VDRE consensus probe
(VDREcon) using 100 ng (Cold VDREcon_1) or 200 ng (Cold VDREcon_2).
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out of the cell or intracellular compartments. The metal ion
transporter families SLC39 (ZIP) and SLC30 (ZnT) work in opposite
directions to ensure zinc and manganese homeostasis. ZIP
transporters increase cytoplasmic zinc concentrations via zinc
uptake from the extracellular environment or efﬂux from
intracellular storage compartments, while ZnT transporters move
these ions out of the cell or into intracellular storage organelles,
thereby decreasing their cytoplasmic levels [31,36]. There are
10 identiﬁed members of the ZnT family: ZnT1-10.
The gene encoding ZnT10, SLC30A10, is chieﬂy expressed in the
liver, brain, testis and small intestine [7,8] and is regulated by zinc
via a zinc transcriptional regulatory element (ZTRE) [49]. Our
results indicate that SLC30A10 expression is modulated by vitamin
D3,via the VDR. Upon treatment with vitamin D3, we observed an
increase in SLC30A10 mRNA and protein in Caco-2 cells and in
human biopsies, prompting us to investigate a possible involve-
ment of the VDR. The augmentation in SLC30A10 promoter activity
strictly in the presence of the VDR, RXR and vitamin D3 (Fig. 5), as
well as EMSA identiﬁcation of VDREs located in the 50-ﬂanking
region of the SLC30A10 gene (Fig. 6), supported a VDR-mediated
transactivation.
In view of the pandemic vitamin D deﬁciency and widespread
supplementation, it would be interesting to understand the
physiological and pharmacological implications, if any, of this
SLC30A10/ZnT10 induction by vitamin D3. Theoretically, the
ultimate consequence would be a reduction in cytoplasmic levels
of Zn and Mn concomitant with a rise in their levels in storage
organelles and in the extracellular ﬂuid. It would be tempting to
speculate that vitamin D3 stimulates release of these metal ions
into the circulation, to reach organs in need, while aiding vitamin D
in some of its physiological actions. For instance, vitamin D3, Zn
and Mn have osteoprotective properties and stimulate bone
formation [12]. Zinc has been suggested as an additionalsupplement in treatment and prevention of osteoporosis [50]
and a possible participation of Mn in the mechanism of
osteoporosis has been proposed [51]. It is still unclear whether
there is a synergism between vitamin D3, Zn and Mn, but
symptoms of some pathologies may suggest an important link
between these nutrients. In inﬂammatory bowel disease (IBD),
celiac disease and food protein-induced gastrointestinal allergy
(FPGIA), vitamin D and zinc levels are particularly reduced [52–54].
Although poor absorption is a hallmark of these intestinal diseases,
a modulatory effect of these nutrients, whereby imbalance of one
nutrient can affect circulating concentrations of the other, cannot
be excluded. Associations between childhood wheezing and
asthma, when maternal intake of vitamin D and zinc, as well as
vitamin E, is inadequate, have also been described [55] and zinc
and vitamin D monitoring and supplementation have been
suggested as a potential way to control wheezing in children [56].
Mutations in SLC30A10, which prevent ZnT10 expression and
function, lead to a toxic accumulation of Mn in the brain, known as
manganism. This is a Parkinson-like disease, except patients are
not responsive to treatment with L-DOPA or dopamine agonists
[57], but instead, to chelation therapy [58]. Hypovitaminosis D is
prevalent in patients with early Parkinson’s disease (PD) [59,60]
and serum 25OHD levels have been shown to correlate with the
severity of PD [61]. It would be revealing to examine whether in
these patients, hypovitaminosis D would also affect
ZnT10 expression or function, and if Mn levels are altered as a
consequence.
Our current data corroborates previous reports and brings to
light new ﬁndings on the molecular role of vitamin D3 on the
homeostasis of iron, manganese and several nutrient/drug trans-
porters, as well as phase I and II enzymes. In particular for zinc and
manganese homeostasis, our ﬁnding that vitamin D3 regulates
SLC30A10 could trigger future work that assesses a possible role of
Zn or Mn supplementation or chelation, alongside vitamin D3
T. Claro da Silva et al. / Journal of Steroid Biochemistry & Molecular Biology 163 (2016) 77–87 87administration, in the treatment of speciﬁc illnesses, such as
osteoporosis and PD.
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